OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Nasioudis on the Use of NGS to Identify the Molecular Profile of Endometroid Ovarian Cancer

March 29th 2023

Dimitrios Nasioudis, MD, discusses how the use of next-generation sequencing can help identify the unique molecular profile of endometroid ovarian cancer.

Dr Buckingham on the Use of Patient-reported Outcomes to Predict Frailty in Patients With Ovarian Cancer

March 29th 2023

Lindsey K. Buckingham, MD, discusses an investigation into the use of patient-reported outcomes from the cancer-specific Geriatric Assessment (GA) to predict frailty in women with ovarian cancer, as well as planning the next steps for this research in other gynecologic cancers.

Dr Slomovitz on the Investigation of Letrozole Plus Ribociclib in Low-Grade Serous Ovarian Carcinoma

March 28th 2023

Brian M. Slomovitz, MD, discusses the evaluation of letrozole and ribociclib from the phase 2 GOG 3026 trial in recurrent low-grade serous ovarian carcinoma.

Dr Westin on Outcomes of the SOLAR Trial in RAS-Mutant Gynecological Malignances

March 28th 2023

Shannon N. Westin, MD, MPH, FACOG, discusses the outcomes of the phase 1b SOLAR trial, which examined olaparib with selumetinib in patients with RAS-mutant gynecologic malignancies and other solid tumors.

Dr Soliman on the Use of ctDNA as a Clinical Trial End Point in Endometrial Cancer

March 28th 2023

Pamela T. Soliman, MD, MPH, discusses the use of circulating tumor DNA a clinical trial end point in endometrial cancer.

Dr Dietrich on the Importance of Mutational Profiling in NSCLC Treatment

March 28th 2023

Martin F. Dietrich, MD, PhD, discusses how mutational profiling can inform subsequent treatment selection for patients with non–small cell lung cancer.

Dr Bockorny on Botensilimab Plus Balstilimab in Ovarian Cancer

March 28th 2023

Bruno B. Bockorny, MD, discusses findings from a phase 1a/b trial with the combination of botensilimab and balstilimab in patients with recurrent platinum-refractory or platinum-resistant ovarian cancer.

Dr Mirza on Dostarlimab Plus Chemotherapy in Endometrial Cancer

March 28th 2023

Mansoor Raza Mirza, MD, discusses findings from the phase 3 RUBY trial in patients with endometrial cancer.

Dr Muslimani on the Implications of the MOUNTAINEER Trial in HER2+ mCRC

March 27th 2023

Alaa Muslimani, MD, discusses the unmet needs for patients with HER2-positve metastatic colorectal cancer and highlights the implications of the phase 2 MOUNTAINEER trial in this patient population.

Dr Sokolova on Rucaparib vs Physician’s Choice Therapy in BRCA+ mCRPC

March 27th 2023

Alexandra Sokolova, MD,discusses the evaluation of rucaparib vs physician’s choice standard of care therapy in patients with BRCA-positive metastatic castration-resistant prostate cancer.

Dr Kin on the Withdrawal of Belantamab Mafodotin in R/R Multiple Myeloma

March 27th 2023

Andrew Kin, MD, discusses the withdrawal of the United States marketing authorization of belantamab mafodotin for the treatment of patients with relapsed/refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.

Dr Dorigo on the Clinical Benefit with Maveropepimut-S in Recurrent Ovarian Cancer

March 27th 2023

Oliver Dorigo, MD, PhD, discusses the clinical efficacy of maveropepimut-S in patients with recurrent ovarian cancer.

Dr Polan on Perioperative Outcomes With Supracervical or Total Hysterectomy Plus Colorectal Resection

March 27th 2023

Rosa M. Polan, MD, discusses key data from a comparison of perioperative outcomes with supracervical and total hysterectomy performed with concurrent colorectal resection in women.

Dr Coleman on Response Rates With Mirvetuximab Soravtansine in Ovarian Cancer

March 27th 2023

Robert L. Coleman, MD, FACOG, FACS, discusses an analysis of the phase 3 SORAYA trial evaluating response rates in patients with platinum-resistant ovarian cancer who received mirvetuximab soravtansine at different points in their disease course.

Dr Matulonis on Second-line Maintenance Therapy With Niraparib in Ovarian Cancer

March 27th 2023

Ursula A. Matulonis, MD, discusses final overall survival results from the phase 3 NOVA trial in patients with ovarian cancer.

Dr. Cortes on Defining Fitness in Patients With Hematologic Malignancies

March 24th 2023

Jorge E. Cortes, MD, discusses the importance of defining fitness in patients with hematologic malignancies prior to treatment selection.

Dr Randall on the Presentation and Symptoms of Mesenchymal Chondrosarcoma

March 24th 2023

R. Lor Randall, MD, FACS, discusses the potential symptoms and presentation of mesenchymal chondrosarcoma, as well as highlighted recent case studies that he consulted on for patients with mesenchymal chondrosarcoma.

Dr Carey on Response-Guided Therapy in HER2+ Breast Cancer

March 24th 2023

Lisa A. Carey MD, ScM, FASCO, discusses the varying approaches to response-guided therapy in HER2-positive breast cancer.

Dr Vidal on the Need for Improved Clinical Trial Representation in Breast Cancer

March 24th 2023

Gregory Vidal, MD, PhD, explains why clinical trials need to be more representative of the whole breast cancer population, in order to account for differences in biology and social determinants.

Dr Hill on Efficacy of Dostarlimab in dMMR Locally Advanced Rectal Cancer

March 24th 2023

Joshua Hill, MD, MS, discussed the early efficacy of dostarlimab in mismatch repair–deficient locally advanced rectal cancer.